Novel Potential Treatment Designed to Address Overactivation of the Innate Immune System
VIB7734 potentially represents a novel treatment for autoimmune diseases caused by the overproduction of type I interferons and other cytokines secreted by a type of dendritic cell called pDCs. VIB7734 is designed to target and bind to ILT7, a cell surface molecule specific to pDCs, leading to their depletion. The benefits are multifold as this depletion may also decrease other inflammatory cytokines such as TNF-a and IL-6, which are critical to the pathogenesis of a number of autoimmune diseases.
We recently completed our Phase 1b study multiple ascending dose trial, which included a cohort of patients with systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), Sjögren’s syndrome, systemic sclerosis, polymyositis and dermatomyositis, as well as separate cohorts of patients with CLE in the presence of absence of SLE. Data demonstrated VIB7734’s potential to reduce lesions in lupus patients and informed our decision to pursue SLE for our planned Phase 2 trial.